Thiogenesis Therapeutics Corp. (TTI : TSX-V)
Common Stock
$0.51
CAD
-0.01 (-1.92%)
Last updated: 2026-09-03
Get TTI alerts:
TTI
Thiogenesis Therapeutics Corp.
WealthAwesomePerformance
1 Day
-1.92%
1 Week
+0.00%
1 Month
-5.56%
YTD
-21.54%
Key Statistics
Market Cap
$35.69M
52W High
$0.81
52W Low
$0.44
P/E Ratio
-
50 Day MA
$0.54
200 Day MA
$0.56
Beta
0.56
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/3/2026 | $0.51 | $0.51 | $0.50 | $0.51 | $0.51 | 156,000 |
| 9/2/2026 | $0.52 | $0.52 | $0.52 | $0.52 | $0.52 | 1,000 |
| 8/31/2026 | $0.55 | $0.55 | $0.54 | $0.54 | $0.54 | 2,315 |
| 8/24/2026 | $0.52 | $0.52 | $0.51 | $0.51 | $0.51 | 13,500 |
| 8/21/2026 | $0.51 | $0.52 | $0.51 | $0.51 | $0.51 | 30,000 |
| 8/20/2026 | $0.50 | $0.50 | $0.50 | $0.50 | $0.50 | 205,666 |
| 8/19/2026 | $0.58 | $0.58 | $0.55 | $0.55 | $0.55 | 50,500 |
| 8/14/2026 | $0.56 | $0.56 | $0.55 | $0.55 | $0.55 | 13,000 |
| 8/13/2026 | $0.57 | $0.57 | $0.57 | $0.57 | $0.57 | 28,000 |
| 8/11/2026 | $0.56 | $0.56 | $0.55 | $0.55 | $0.55 | 3,888 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TTI's historical volatility
30-Day Vol
59.1%
Annualized
90-Day Vol
59.1%
Annualized
Trend (90d)
-24.0%
Annualized drift
90d Mean
C$0.47
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.50 | C$0.40 – C$0.61 |
| 60 trading days | C$0.48 | C$0.36 – C$0.64 |
| 90 trading days | C$0.47 | C$0.33 – C$0.67 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- -181.53%
- EPS (Diluted)
- -0.12
- Book Value
- 0.10
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About TTI
Market movers
Recent TSX-V movers
Top 1-day gainers — updated from our Canadian movers feed.
TTI.V news timeline
1 article covering TTI.V, most recent first
Latest